MedTrace Logo

Effect of Sumatriptan on Levcromakalim-Induced Symptoms in Individuals With Migraine

NCT05211050 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-01-22

No results posted yet for this study

Summary

The study aims to explore the effects of Sumatriptan on Levcromakalim-induced migraine in individuals with migraine without aura.

Conditions

Interventions

DRUG

Levcromakalim

20 min infusion of 1 mg Levcromakalim followed by either sumatriptan or placebo.

DRUG

Sumatriptan

10 min infusion of 4 mg sumatriptan.

DRUG

Saline

10 min infusion of isotonic saline (placebo).

Sponsors & Collaborators

  • Danish Headache Center

    lead OTHER

Principal Investigators

  • Messoud Ashina, Prof. · Danish Headache Center

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-15
Primary Completion
2023-11-05
Completion
2023-11-05

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05211050 on ClinicalTrials.gov